Researchers trace GLP-1 craving effects to the brain's lateral septum

Researchers say they are homing in on a small brain region, the lateral septum, as a likely control point behind the reduced cravings that many people report while taking GLP-1 drugs such as Ozempic and Wegovy ^[1]. The region sits between memory circuits and the brain's dopamine-driven reward system, and it is described as being heavily packed with GLP-1 receptors ^[1].

GLP-1 drugs were built to help control blood sugar in type 2 diabetes and later became known for producing weight loss in some cases close to what is seen after bariatric surgery ^[1]. But researchers have also documented a separate effect: human studies show these drugs can reduce alcohol consumption, and animal studies suggest they lower use of cocaine, amphetamines, opiates, and nicotine ^[1].

For years, the brain regions most associated with reward, the ventral tegmental area and the nucleus accumbens, were the obvious places to look for how this happens. But according to the report, those regions do not have much density of GLP-1 receptors, so scientists began looking further upstream ^[1].

That search led to the lateral septum, a structure first studied in the 1950s, when researchers Joseph Brady and Walle Nauta linked damage there to increased aggression in animals, a phenomenon they called "septal rage" ^[1]. More recent work has repositioned the lateral septum as a hub with wide-ranging connections, receiving heavy input from the hippocampus, the brain region responsible for forming long-term memories and for tracking a person's sense of place and time ^[1].

Recent studies cited in the report found that the lateral septum contains its own "place cells" that respond strongly to rewards, effectively layering information about what is rewarding onto the hippocampus's sense of where and when a person is ^[1]. The lateral septum then relays that combined signal to the brain's dopamine-producing reward machinery, according to the researchers ^[1]. Because the region is described as loaded with GLP-1 receptors, scientists say it is positioned to be a direct target of GLP-1 drugs ^[1].

Direct evidence is also emerging from animal research. GLP-1 activation in the lateral septum has been shown to reduce food consumption in mice, and a separate study earlier this year reported the same effect for alcohol consumption ^[1]. The report's author, a university lecturer whose lab studies the region, says the lab's own research this year found GLP-1 drugs reduce a type of brain activity in the lateral septum that may limit its ability to communicate effectively with other brain regions ^[1].

Why it matters for patients

Many patients on semaglutide or tirzepatide already describe feeling less interested in alcohol, snacking, or other habitual behaviors, sometimes called "food noise" going quiet. This research offers a possible biological explanation for that experience, tracing it to a specific brain circuit rather than treating it as a side effect with no clear cause ^[1].

The findings are described as reshaping scientific understanding of the reward system generally, which could eventually open new treatment approaches for obesity, alcohol dependence, and other substance use, according to the report ^[1]. That said, this is laboratory and early-stage research, largely based on animal studies and human observational data on alcohol use, not a clinical trial proving GLP-1 drugs treat addiction ^[1]. Whether findings in mice and rats translate into approved treatments for humans is not addressed in this report.

What happens next

The report does not include a timeline for further human trials or regulatory review targeting addiction treatment specifically. It notes that GLP-1 drugs' effects on lateral septum activity were shown in the lab author's own research this year, alongside a separate 2026 study on alcohol consumption, suggesting this remains an active and fast-moving area of study ^[1]. No specific dates for next studies or drug applications are given in the source.